Literature DB >> 28373198

Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Russell R Kempker1, M Tobias Heinrichs2, Ketino Nikolaishvili3, Irina Sabulua3, Nino Bablishvili3, Shota Gogishvili3, Zaza Avaliani3, Nestani Tukvadze3, Brent Little4, Adam Bernheim4, Timothy D Read5, Jeannette Guarner6, Hartmut Derendorf2, Charles A Peloquin2, Henry M Blumberg5,7, Sergo Vashakidze3.   

Abstract

Improved knowledge regarding the tissue penetration of antituberculosis drugs may help optimize drug management. Patients with drug-resistant pulmonary tuberculosis undergoing adjunctive surgery were enrolled. Serial serum samples were collected, and microdialysis was performed using ex vivo lung tissue to measure pyrazinamide concentrations. Among 10 patients, the median pyrazinamide dose was 24.7 mg/kg of body weight. Imaging revealed predominant lung lesions as cavitary (n = 6 patients), mass-like (n = 3 patients), or consolidative (n = 1 patient). On histopathology examination, all tissue samples had necrosis; eight had a pH of ≤5.5. Tissue samples from two patients were positive for Mycobacterium tuberculosis by culture (pH 5.5 and 7.2). All 10 patients had maximal serum pyrazinamide concentrations within the recommended range of 20 to 60 μg/ml. The median lung tissue free pyrazinamide concentration was 20.96 μg/ml. The median tissue-to-serum pyrazinamide concentration ratio was 0.77 (range, 0.54 to 0.93). There was a significant inverse correlation between tissue pyrazinamide concentrations and the amounts of necrosis (R = -0.66, P = 0.04) and acid-fast bacilli (R = -0.75, P = 0.01) identified by histopathology. We found good penetration of pyrazinamide into lung tissue among patients with pulmonary tuberculosis with a variety of radiological lesion types. Our tissue pH results revealed that most lesions had a pH conducive to pyrazinamide activity. The tissue penetration of pyrazinamide highlights its importance in both drug-susceptible and drug-resistant antituberculosis treatment regimens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  drug penetration; drug resistance; microdialysis; pharmacology; pyrazinamide; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28373198      PMCID: PMC5444116          DOI: 10.1128/AAC.00226-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

Review 2.  Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.

Authors:  Linda M Parsons; Akos Somoskövi; Cristina Gutierrez; Evan Lee; C N Paramasivan; Alash'le Abimiku; Steven Spector; Giorgio Roscigno; John Nkengasong
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  Absorption, metabolism and excretion of pyrazinamide in man.

Authors:  G A Ellard
Journal:  Tubercle       Date:  1969-06

Review 4.  Mechanisms of Pyrazinamide Action and Resistance.

Authors:  Ying Zhang; Wanliang Shi; Wenhong Zhang; Denis Mitchison
Journal:  Microbiol Spectr       Date:  2014-08

5.  In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

Authors:  J Woo; W Cheung; R Chan; H S Chan; A Cheng; K Chan
Journal:  Clin Biochem       Date:  1996-04       Impact factor: 3.281

6.  Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.

Authors:  Russell R Kempker; Aline B Barth; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Ravi Shankar P Singh; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

7.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

8.  Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

Authors:  Hye-Ryoun Kim; Seung Sik Hwang; Hyun Ji Kim; Sang Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

9.  The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse.

Authors:  C D Hamilton; J E Stout; P C Goodman; A Mosher; R Menzies; N W Schluger; A Khan; J L Johnson; A N Vernon
Journal:  Int J Tuberc Lung Dis       Date:  2008-09       Impact factor: 2.373

10.  Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis.

Authors:  Melissa D Chengalroyen; Germar M Beukes; Bhavna G Gordhan; Elizabeth M Streicher; Gavin Churchyard; Richard Hafner; Robin Warren; Kennedy Otwombe; Neil Martinson; Bavesh D Kana
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

View more
  26 in total

1.  Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.

Authors:  M Tobias Heinrichs; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Brent P Little; Adam Bernheim; Jeannette Guarner; Charles A Peloquin; Henry M Blumberg; Hartmut Derendorf; Russell R Kempker
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

Review 2.  Acid Fasting: Modulation of Mycobacterium tuberculosis Metabolism at Acidic pH.

Authors:  Jacob J Baker; Shelby J Dechow; Robert B Abramovitch
Journal:  Trends Microbiol       Date:  2019-07-16       Impact factor: 17.079

3.  Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.

Authors:  Navisha Dookie; Kogieleum Naidoo; Nesri Padayatchi
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 4.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

5.  pH Conditions under Which Pyrazinamide Works in Humans.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Brent P Little; Adam Bernheim; Hartmut Derendorf; Henry M Blumberg; Sergo Vashakidze; Charles A Peloquin
Journal:  Eur Respir J       Date:  2018-02-07       Impact factor: 16.671

8.  Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.

Authors:  Keertan Dheda; Laura Lenders; Gesham Magombedze; Shashikant Srivastava; Prithvi Raj; Erland Arning; Paula Ashcraft; Teodoro Bottiglieri; Helen Wainwright; Timothy Pennel; Anthony Linegar; Loven Moodley; Anil Pooran; Jotam G Pasipanodya; Frederick A Sirgel; Paul D van Helden; Edward Wakeland; Robin M Warren; Tawanda Gumbo
Journal:  Am J Respir Crit Care Med       Date:  2018-11-01       Impact factor: 21.405

Review 9.  Cavitary tuberculosis: the gateway of disease transmission.

Authors:  Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai
Journal:  Lancet Infect Dis       Date:  2020-05-05       Impact factor: 25.071

10.  Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.

Authors:  Pooja Gopal; Wilson Nartey; Priya Ragunathan; Jansy Sarathy; Firat Kaya; Michelle Yee; Claudia Setzer; Malathy Sony Subramanian Manimekalai; Véronique Dartois; Gerhard Grüber; Thomas Dick
Journal:  ACS Infect Dis       Date:  2017-10-18       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.